Citi downgrades Acorda Therapeutics

Citi cuts Acorda Therapeutics (ACOR -1.8%) to Neutral from Buy, noting that "any paragraph IV filing could pressure the stock in early 2014 given concerns about Ampyra's patents."

The analysts do note that the company "believes they have strong patent protection that covers Ampyra ... until 2027 [and] should help prevent generic entry."

Nevertheless, concerns about market share and the scope of price increases for the drug (which improves walking in MS patients) lead the firm's analysts to cut their price target to $33 from $37.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs